Analysts Set Kymera Therapeutics, Inc. (NASDAQ:KYMR) PT at $41.20

Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) have been given a consensus recommendation of “Moderate Buy” by the thirteen brokerages that are covering the company, MarketBeat reports. Six investment analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $41.20.

Several brokerages recently issued reports on KYMR. JPMorgan Chase & Co. boosted their price objective on shares of Kymera Therapeutics from $34.00 to $47.00 and gave the company an “overweight” rating in a report on Friday, February 23rd. Bank of America cut shares of Kymera Therapeutics from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $45.00 to $30.00 in a research report on Wednesday, January 3rd. Oppenheimer began coverage on Kymera Therapeutics in a research report on Monday, April 22nd. They issued an “outperform” rating and a $53.00 target price on the stock. Stifel Nicolaus upped their price target on Kymera Therapeutics from $35.00 to $55.00 and gave the stock a “buy” rating in a research note on Friday, February 23rd. Finally, Truist Financial lifted their price objective on Kymera Therapeutics from $41.00 to $54.00 and gave the company a “buy” rating in a research note on Friday, March 1st.

Kymera Therapeutics Stock Performance

NASDAQ:KYMR opened at $34.66 on Tuesday. Kymera Therapeutics has a one year low of $9.60 and a one year high of $45.31. The stock has a market cap of $2.13 billion, a PE ratio of -13.75 and a beta of 2.27. The stock has a 50 day moving average price of $38.83 and a 200 day moving average price of $28.91.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings results on Thursday, February 22nd. The company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.19. Kymera Therapeutics had a negative net margin of 187.00% and a negative return on equity of 34.83%. The business had revenue of $47.90 million during the quarter, compared to analysts’ expectations of $41.94 million. During the same quarter in the prior year, the company posted ($0.60) EPS. The business’s revenue for the quarter was up 197.5% on a year-over-year basis. As a group, analysts predict that Kymera Therapeutics will post -3.15 earnings per share for the current fiscal year.

Insider Transactions at Kymera Therapeutics

In related news, CFO Bruce N. Jacobs sold 3,934 shares of the firm’s stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $41.86, for a total value of $164,677.24. Following the sale, the chief financial officer now owns 142,351 shares of the company’s stock, valued at $5,958,812.86. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other Kymera Therapeutics news, Director Bruce Booth sold 71,764 shares of the firm’s stock in a transaction on Friday, March 15th. The stock was sold at an average price of $40.46, for a total value of $2,903,571.44. Following the sale, the director now directly owns 806,697 shares in the company, valued at $32,638,960.62. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Bruce N. Jacobs sold 3,934 shares of the company’s stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $41.86, for a total value of $164,677.24. Following the transaction, the chief financial officer now directly owns 142,351 shares of the company’s stock, valued at $5,958,812.86. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 474,051 shares of company stock valued at $19,624,211. 16.67% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Kymera Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in KYMR. Principal Financial Group Inc. raised its holdings in Kymera Therapeutics by 4.7% during the first quarter. Principal Financial Group Inc. now owns 12,098 shares of the company’s stock worth $486,000 after purchasing an additional 547 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its stake in Kymera Therapeutics by 83.0% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 11,753 shares of the company’s stock worth $472,000 after acquiring an additional 5,330 shares in the last quarter. Congress Asset Management Co. MA lifted its position in Kymera Therapeutics by 1.2% in the first quarter. Congress Asset Management Co. MA now owns 45,836 shares of the company’s stock valued at $1,843,000 after acquiring an additional 533 shares during the last quarter. Vanguard Group Inc. boosted its stake in Kymera Therapeutics by 1.8% in the fourth quarter. Vanguard Group Inc. now owns 3,997,564 shares of the company’s stock valued at $101,778,000 after acquiring an additional 72,351 shares in the last quarter. Finally, Goldman Sachs Group Inc. boosted its stake in Kymera Therapeutics by 229.6% in the fourth quarter. Goldman Sachs Group Inc. now owns 674,655 shares of the company’s stock valued at $17,177,000 after acquiring an additional 469,947 shares in the last quarter.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.